Takeda Pharmaceutical

TAK · TOKYO

$20.24−$0.12 (−0.59%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $20.36

Latest news

NewsOct 23, 7:33 AM ET
Takeda Announces Results From Its Phase 3 G-HOPE-001 Study Of Arcotatug Tavatecan In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma; Arcotatug Tavatecan Met Dual Primary Endpoints Of Overall Survival And Progression-Free Survival, Showing Significant Improvements
Press releaseOct 23, 7:30 AM ETBusiness Wire
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
NewsOct 19, 8:38 AM ETVandana Singh
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
Press releaseOct 19, 5:30 AM ETBusiness Wire
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
NewsOct 16, 1:52 PM ETVandana Singh
Ascentage Pharma Stock Could More Than Double: Analyst
Press releaseOct 14, 8:30 PM ETBusiness Wire
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Press releaseOct 14, 8:00 AM ETBusiness Wire
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
Press releaseSep 30, 1:00 AM ETBusiness Wire
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
Press releaseSep 22, 9:30 AM ETBusiness Wire
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
NewsSep 21, 10:00 PM ETRadhika Anilkumar Nadig
Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development
Press releaseSep 18, 1:00 AM ETBusiness Wire
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
NewsSep 17, 9:06 AM ET
Full Transcript: Takeda Pharmaceutical Co Q1 2026 Earnings Call
Press releaseSep 14, 3:00 AM ETBusiness Wire
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
Press releaseSep 9, 8:24 AM ETBusiness Wire
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
NewsAug 31, 12:38 PM ETVandana Singh
Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug
Press releaseAug 28, 6:40 PM ETBusiness Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
Press releaseAug 24, 2:36 AM ETBusiness Wire
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
NewsAug 13, 1:07 PM ETVandana Singh
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
NewsAug 13, 4:33 AM ETSnigdha Gairola
Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’
NewsAug 6, 11:16 AM ETVandana Singh
Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval
Press releaseAug 5, 6:10 PM ETBusiness Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
NewsJul 30, 2:50 AM ET
Takeda Pharmaceutical Q1 Adj. EPS $0.48 Beats $0.39 Estimate, Sales $7.655B Beat $7.060B Estimate
Press releaseJul 30, 2:37 AM ETBusiness Wire
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
NewsJul 17, 1:08 PM ETVandana Singh
Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials
Press releaseJul 16, 6:00 PM ETBusiness Wire
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
NewsJul 16, 11:23 AM ETBamboo Works
World's First End-To-End AI Drug Developer To Power Into Black On Lucrative Partnerships
Press releaseJul 12, 7:00 PM ETBusiness Wire
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
NewsJul 2, 1:38 PM ETVandana Singh
Takeda Makes Fresh AI Drug Discovery Bet With Insilico Medicine
NewsJun 24, 2:22 PM ETVandana Singh
This $300 Million Biotech May Be Deeply Mispriced: Analyst
Press releaseJun 24, 3:05 AM ETBusiness Wire
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
Press releaseJun 15, 12:00 PM ETBusiness Wire
New Pivotal Study Data Show Takeda's Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
NewsJun 12, 10:47 AM ETVandana Singh
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
NewsJun 11, 1:12 PM ETVandana Singh
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med
NewsMay 13, 11:38 AM ETVandana Singh
Takeda's Next Wave Of Drugs Has Investors Watching Closely
NewsMay 13, 7:11 AM ET
Earnings Scheduled For May 13, 2026
NewsMay 13, 4:47 AM ET
Takeda Pharmaceutical Q4 Adj. EPS $0.28 Beats $0.21 Estimate, Sales $6.978B Miss $7.050B Estimate
NewsFeb 9, 12:59 PM ETVandana Singh
Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Takeda Announces Results From Its Phase 3 G-HOPE-001 Study Of Arcotatug Tavatecan In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma; Arcotatug Tavatecan Met Dual Primary Endpoints Of Overall Survival And Progression-Free Survival, Showing Significant Improvements

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study

Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Ascentage Pharma Stock Could More Than Double: Analyst

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026

Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

Full Transcript: Takeda Pharmaceutical Co Q1 2026 Earnings Call

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug

Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’

Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda Pharmaceutical Q1 Adj. EPS $0.48 Beats $0.39 Estimate, Sales $7.655B Beat $7.060B Estimate

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

World's First End-To-End AI Drug Developer To Power Into Black On Lucrative Partnerships

Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products

Takeda Makes Fresh AI Drug Discovery Bet With Insilico Medicine

This $300 Million Biotech May Be Deeply Mispriced: Analyst

Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO

New Pivotal Study Data Show Takeda's Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1

Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data

Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med

Takeda's Next Wave Of Drugs Has Investors Watching Closely

Earnings Scheduled For May 13, 2026

Takeda Pharmaceutical Q4 Adj. EPS $0.28 Beats $0.21 Estimate, Sales $6.978B Miss $7.050B Estimate

Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery